$OCGN
Ocugen, Inc. Stock $ocgn

$ocgn Overview Financials Valuation SEC Filings Company Website

2016 Q4 Form 10-Q Financial Statement

#000119312516765874 Filed on November 10, 2016

Income Statement

Concept	2016 Q4	2016 Q3	2015 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.390M	$1.770M	$2.190M
YoY Change	7.17%	-19.18%	28.82%
% of Gross Profit
Research & Development	$5.320M	$4.880M	$5.848M
YoY Change	-7.8%	-16.55%	-55.82%
% of Gross Profit
Depreciation & Amortization	$400.0K	$404.0K	$414.0K
YoY Change	-6.98%	-2.42%	144.97%
% of Gross Profit
Operating Expenses	$7.710M	$6.648M	$8.039M
YoY Change	-3.63%	-17.3%	-46.19%
Operating Profit		-$6.648M	-$8.039M
YoY Change		-17.3%	-46.19%
Interest Expense	$16.92M	$20.00K	$23.00K
YoY Change	-84700.0%	-13.04%	21.05%
% of Operating Profit
Other Income/Expense, Net	$50.00K	-$2.667M	-$39.00K
YoY Change	-600.0%	6738.46%	-101.31%
Pretax Income	$9.060M	-$9.320M	-$8.080M
YoY Change	-208.5%	15.35%	-32.5%
Income Tax
% Of Pretax Income
Net Earnings	$9.060M	-$9.315M	-$8.078M
YoY Change	-208.5%	15.31%	-32.54%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share	$31.24M	-$42.36M	-$36.73M
COMMON SHARES
Basic Shares Outstanding	15.93M shares	13.27M shares	0.000 shares
Diluted Shares Outstanding

Balance Sheet

Concept	2016 Q4	2016 Q3	2015 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.91M	$37.99M	$37.72M
YoY Change	3.2%	0.72%	1057.06%
Cash & Equivalents	$31.91M	$37.99M	$37.72M
Short-Term Investments
Other Short-Term Assets	$68.00K	$200.0K	$370.0K
YoY Change	-65.13%	-45.95%	-88.1%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$32.08M	$38.20M	$38.09M
YoY Change	2.71%	0.28%	497.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$3.860M	$4.263M	$5.513M
YoY Change	-25.95%	-22.67%	63.11%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$140.0K	$140.0K	$1.190M
YoY Change	0.0%	-88.24%	-29.17%
Total Long-Term Assets	$3.997M	$4.600M	$7.213M
YoY Change	-27.98%	-36.23%	28.12%
TOTAL ASSETS
Total Short-Term Assets	$32.08M	$38.20M	$38.09M
Total Long-Term Assets	$3.997M	$4.600M	$7.213M
Total Assets	$36.08M	$42.80M	$45.30M
YoY Change	-1.92%	-5.53%	277.51%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.588M	$1.665M	$2.001M
YoY Change	-21.54%	-16.79%	-54.11%
Accrued Expenses	$2.097M	$4.290M	$2.449M
YoY Change	45.22%	75.17%	50.25%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due	$580.0K	$580.0K	$580.0K
YoY Change	0.0%	0.0%	544.44%
Total Short-Term Liabilities	$5.171M	$7.209M	$6.690M
YoY Change	-18.68%	7.76%	-61.95%
LONG-TERM LIABILITIES
Long-Term Debt	$180.0K	$320.0K	$910.0K
YoY Change	-76.32%	-64.84%	145.95%
Other Long-Term Liabilities	$17.16M	$31.23M	$1.530M
YoY Change	1067.35%	1941.18%	-94.0%
Total Long-Term Liabilities	$17.34M	$31.55M	$2.440M
YoY Change	677.58%	1193.03%	-90.56%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.171M	$7.209M	$6.690M
Total Long-Term Liabilities	$17.34M	$31.55M	$2.440M
Total Liabilities	$22.51M	$38.76M	$9.125M
YoY Change	162.12%	324.76%	-78.99%
SHAREHOLDERS EQUITY
Retained Earnings	-$181.8M	-$190.8M	-$157.2M
YoY Change	9.79%	21.38%
Common Stock	$195.3M	$194.9M	$193.4M
YoY Change	0.81%	0.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$13.57M	$4.036M	$36.18M
YoY Change
Total Liabilities & Shareholders Equity	$36.08M	$42.80M	$45.30M
YoY Change	-1.92%	-5.53%	277.51%

Cashflow Statement

Concept	2016 Q4	2016 Q3	2015 Q3
OPERATING ACTIVITIES
Net Income	$9.060M	-$9.315M	-$8.078M
YoY Change	-208.5%	15.31%	-32.54%
Depreciation, Depletion And Amortization	$400.0K	$404.0K	$414.0K
YoY Change	-6.98%	-2.42%	144.97%
Cash From Operating Activities	-$5.900M	-$5.460M	-$6.880M
YoY Change	-15.59%	-20.64%	146.59%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	-$10.00K	-$500.0K
YoY Change	-100.0%	-98.0%	-64.03%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$0.00	-$10.00K	-$500.0K
YoY Change	-100.0%	-98.0%	-64.03%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-190.0K	27.53M	-120.0K
YoY Change	26.67%	-23041.67%	-64.71%
NET CHANGE
Cash From Operating Activities	-5.900M	-5.460M	-6.880M
Cash From Investing Activities	0.000	-10.00K	-500.0K
Cash From Financing Activities	-190.0K	27.53M	-120.0K
Net Change In Cash	-6.090M	22.06M	-7.500M
YoY Change	-16.23%	-394.13%	65.93%
FREE CASH FLOW
Cash From Operating Activities	-$5.900M	-$5.460M	-$6.880M
Capital Expenditures	$0.00	-$10.00K	-$500.0K
Free Cash Flow	-$5.900M	-$5.450M	-$6.380M
YoY Change	-13.99%	-14.58%	355.71%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2016Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	349000
CY2016Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	15930708	shares
CY2012Q3	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	117000
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37723000
CY2015Q3	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2016Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2016Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9256000
CY2016Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2016Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	15871965	shares
CY2016Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15871965	shares
CY2016Q3	us-gaap	Assets Assets	42795000
CY2016Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	133000
CY2016Q3	us-gaap	Assets Current AssetsCurrent	38195000
CY2016Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2016Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2016Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	194713000
CY2016Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37994000
CY2016Q3	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	2802000
CY2016Q3	us-gaap	Common Stock Value CommonStockValue	159000
CY2016Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	1665000
CY2016Q3	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	135000
CY2016Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2016Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q3	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2016Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2016Q3	us-gaap	Noncurrent Assets NoncurrentAssets	4263000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000
CY2016Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	24158.8693	shares
CY2016Q3	us-gaap	Liabilities Liabilities	38759000
CY2016Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42795000
CY2016Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	200000
CY2016Q3	us-gaap	Loans Payable LoansPayable	907000
CY2016Q3	us-gaap	Liabilities Current LiabilitiesCurrent	7209000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	178000
CY2016Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	712000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	146000
CY2016Q3	us-gaap	Product Warranty Accrual Noncurrent ProductWarrantyAccrualNoncurrent	30165000
CY2016Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	583000
CY2016Q3	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	407000
CY2016Q3	us-gaap	Preferred Stock Value PreferredStockValue
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	266000
CY2016Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	324000
CY2016Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4263000
CY2016Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13519000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	7.05
CY2016Q3	us-gaap	Stockholders Equity StockholdersEquity	4036000
CY2016Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2744000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	6.77
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	449478	shares
CY2016Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-190836000
CY2016Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	201000
CY2016Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	24158.8693	shares
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	253000
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	130000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	1248103	shares
CY2016Q3	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	6.78
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1329064	shares
CY2016Q3	hsgx	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageGrantDateFairValue	4.15
CY2016Q3	hsgx	Fair Value Input Amount Transfer Between Levels FairValueInputAmountTransferBetweenLevels	0
CY2016Q3	hsgx	Accrued Liability Current Excluding Lease Incentive Payable AccruedLiabilityCurrentExcludingLeaseIncentivePayable	1484000
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	58060000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	630000
CY2015Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7989000
CY2015Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2015Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	13273470	shares
CY2015Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	13273470	shares
CY2015Q4	us-gaap	Assets Assets	36786000
CY2015Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	451000
CY2015Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	126000
CY2015Q4	us-gaap	Assets Current AssetsCurrent	31236000
CY2015Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	0.01
CY2015Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	193631000
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	30915000
CY2015Q4	us-gaap	Due To Related Parties Noncurrent DueToRelatedPartiesNoncurrent	1546000
CY2015Q4	us-gaap	Common Stock Value CommonStockValue	132000
CY2015Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2024000
CY2015Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	229000
CY2015Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	156138	shares
CY2015Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2015Q4	us-gaap	Loans Payable Current LoansPayableCurrent	583000
CY2015Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q4	us-gaap	Noncurrent Assets NoncurrentAssets	5213000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	430000
CY2015Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0.0000	shares
CY2015Q4	us-gaap	Liabilities Liabilities	8588000
CY2015Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36786000
CY2015Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	200000
CY2015Q4	us-gaap	Loans Payable LoansPayable	1344000
CY2015Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6359000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	178000
CY2015Q4	us-gaap	Incentive From Lessor IncentiveFromLessor	1017000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	583000
CY2015Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	583000
CY2015Q4	us-gaap	Lease Incentive Payable Current LeaseIncentivePayableCurrent	407000
CY2015Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2015Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	761000
CY2015Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5213000
CY2015Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	13202000
CY2015Q4	us-gaap	Stockholders Equity StockholdersEquity	28198000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7.32
CY2015Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-165565000
CY2015Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	321000
CY2015Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0.0000	shares
CY2015Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	137000
CY2015Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1229339	shares
CY2015Q4	hsgx	Accrued Liability Current Excluding Lease Incentive Payable AccruedLiabilityCurrentExcludingLeaseIncentivePayable	1444000
CY2014Q4	hsgx	Class Of Warrant Or Right Number Of Securities Surrendered ClassOfWarrantOrRightNumberOfSecuritiesSurrendered	5839	shares
CY2012Q3	hsgx	Class Of Warrant Or Right Exercisable Expiration Period ClassOfWarrantOrRightExercisableExpirationPeriod	P10Y
CY2016Q3	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	27700000
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	15000
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-20337000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.79
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	854000
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6035000
	us-gaap	Depreciation Depreciation	1182000
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	857000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-170000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-59000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	253000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1545000
	us-gaap	Operating Expenses OperatingExpenses	23505000
	us-gaap	Net Income Loss NetIncomeLoss	-23675000
	us-gaap	Interest Expense InterestExpense	111000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-1818000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-3139000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	260000
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P5Y9M22D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	dei	Entity Central Index Key EntityCentralIndexKey	0001372299
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-431000
	us-gaap	Operating Income Loss OperatingIncomeLoss	-23505000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4518000
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-467000
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	2311000
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-23037000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1818000
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	4738000
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.633	pure
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0166	pure
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17470000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	40000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.628	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.55
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0167	pure
	us-gaap	Share Based Compensation ShareBasedCompensation	854000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y15D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13218765	shares
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	191000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-23675000
	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	3056000
	dei	Entity Registrant Name EntityRegistrantName	Histogenics Corporation
	dei	Document Type DocumentType	10-Q
	dei	Document Period End Date DocumentPeriodEndDate	2016-09-30
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	7079000
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.90
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1080000
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2016
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6141000
	us-gaap	Depreciation Depreciation	1267000
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-539000
	us-gaap	Sales Revenue Net SalesRevenueNet	0
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	742000
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2870000
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-298000
	us-gaap	Increase Decrease In Accounts Payable Related Parties IncreaseDecreaseInAccountsPayableRelatedParties	-94000
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	40000
	us-gaap	Operating Expenses OperatingExpenses	22401000
	us-gaap	Net Income Loss NetIncomeLoss	-25271000
	us-gaap	Interest Expense InterestExpense	55000
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-317000
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-358000
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-120000
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 18pt"> <b>Reclassifications</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt"> The Company has reclassified certain prior period amounts to conform to the current period presentation. The amounts reclassified impact Accounts Payable and Accrued Expenses and Accounts Payable due to Intrexon Corporation (“Intrexon”) and Accrued Expenses due to Intrexon for the nine months ended September 30, 2015 and the year ended December 31, 2015.</p> </div>
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue	4.96
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	2.51
	us-gaap	Operating Income Loss OperatingIncomeLoss	-22401000
	us-gaap	Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants	27674000
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	27239000
	us-gaap	Increase Decrease In Due To Related Parties Current IncreaseDecreaseInDueToRelatedPartiesCurrent	1256000
	us-gaap	Nature Of Operations NatureOfOperations	<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b>1. NATURE OF BUSINESS</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b>Organization</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> Histogenics Corporation (the “Company”) was incorporated under the laws of the Commonwealth of Massachusetts on June 28, 2000 and has its principal operations in Waltham, Massachusetts. In 2006, the Company’s board of directors approved a corporate reorganization pursuant to which the Company incorporated as a Delaware corporation. The Company is a regenerative medicine company engaged in developing and commercializing products in the musculoskeletal segment of the marketplace. The Company combines cell therapy and tissue engineering technologies to develop products for tissue repair and regeneration and is initially focused on patients suffering from cartilage-derived pain and immobility. The Company’s most advanced product, NeoCart, is currently in a Phase 3 clinical trial in the United States (the “U.S.”) under a special protocol assessment with the U.S. Food and Drug Administration (“FDA”) for the treatment of knee cartilage damage.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On May 13, 2011, the Company completed the acquisition of ProChon Biotech Ltd. (“ProChon”), a privately-held biotechnology company focused on modulating the fibroblast growth factor system for consideration of $2,224 to enable it to create more effective solutions for tissue regeneration. ProChon’s products combine cell regeneration technologies with proprietary growth factors and biocompatible scaffolds to restore injured or chronically damaged tissues. The acquisition of ProChon provided the Company with access to a significant portfolio of intellectual property, including proprietary cell growth factors, in addition to furthering opportunities for the use of biomaterials to create more effective solutions for regenerating human tissue. The acquisition led to the initial recognition of goodwill, which was subsequently written off in 2011, and intangible assets including IPR&D and a licensing agreement which have been impaired as discussed in Note 2.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On December 18, 2014, the Company formed a wholly owned subsidiary, Histogenics Securities Corporation, under the laws of the Commonwealth of Massachusetts.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> On September 29, 2016, the Company closed a private placement of common stock, preferred stock and warrants, contemplated by a securities purchase agreement dated September 15, 2016, with certain institutional and accredited investors. The net proceeds after deducting placement agent fees and other transaction-related expenses was $27.7 million. (See Note 6 for further discussion of the private placement.) Since its inception, the Company has devoted substantially all of its efforts to product development, recruiting management and technical staff, raising capital, starting up production and building infrastructure and has not yet generated revenues from its planned principal operations. Expenses have primarily been for research and development and related administrative costs.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The Company is subject to a number of risks. The developmental nature of its activities is such that significant inherent risks exist in the Company’s operations. Principal among these risks are the successful development of therapeutics, successfully enrolling patients in its clinical trials in a timely manner, obtaining regulatory approval for any of its product candidates in any jurisdiction, compliance with government regulations, ability to obtain adequate financing, protection of proprietary therapeutics, fluctuations in operating results, dependence on key personnel and collaborative partners, adoption of the Company’s products by the physician community, rapid technological changes inherent in the markets targeted, and substitute products and competition from larger companies.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The condensed consolidated financial statements have been prepared on a going-concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. As shown in the accompanying condensed consolidated financial statements, the Company has incurred losses and cash flow deficits from operations for the nine months ended September 30, 2016 and 2015. The Company has financed operations to date primarily through private placements of equity securities, including the sale of common stock and preferred stock, and the related issuance of warrants in September 2016, the issuance of common stock in the initial public offering completed in December 2014, and borrowings under debt agreements. The Company has incurred losses and negative cash flows from operations resulting in an accumulated deficit at September 30, 2016 of $190.8 million. The Company anticipates that it will continue to incur net losses for the next several years. The Company believes that its existing cash and cash equivalents will be sufficient to fund its projected cash needs into the middle of 2018. The Company will require additional capital to complete the filing of a biologics license application with the FDA and commercialize NeoCart, if approved, and for the future development of its existing product candidates.</p> <p style="MARGIN-BOTTOM: 0px; FONT-SIZE: 1px; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal">  </p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 0pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> <b>Basis of Accounting</b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 6pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The condensed consolidated financial statements are unaudited and have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). However, they do not include all of the information and footnotes required by GAAP for complete financial statements. These interim condensed consolidated financial statements, in the opinion of the Company’s management, reflect all normal recurring adjustments necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods ended September 30, 2016 and 2015. The results of operations for the interim periods are not necessarily indicative of the results of operations to be expected for the full year. These interim financial statements should be read in conjunction with the audited financial statements as of and for the year ended December 31, 2015, and the notes thereto, which are included in the Company’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission (the “SEC”) on March 10, 2016.</p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: "Times New Roman"; WHITE-SPACE: normal; WORD-SPACING: 0px; TEXT-TRANSFORM: none; FONT-WEIGHT: normal; COLOR: rgb(0,0,0); FONT-STYLE: normal; ORPHANS: 2; WIDOWS: 2; MARGIN-TOP: 12pt; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px; font-variant-ligatures: normal; font-variant-caps: normal"> The condensed consolidated financial statements include the accounts of Histogenics Corporation and its wholly-owned subsidiaries, ProChon and Histogenics Securities Corporation. All significant intercompany accounts and transactions are eliminated in consolidation.</p> </div>
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-19843000
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	317000
	us-gaap	Repayments Of Debt RepaymentsOfDebt	437000
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	3685	shares
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y10M24D
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	4.92
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.636	pure
	dei	Trading Symbol TradingSymbol	HSGX
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0159	pure
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	16260000
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	2000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.597	pure
	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	377000
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	214840	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.40
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0139	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	111430	shares
	us-gaap	Share Based Compensation ShareBasedCompensation	1080000
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-8078000
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13279833	shares
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P8Y4M24D
	hsgx	Deferred Rent And Lease Incentive DeferredRentAndLeaseIncentive	400000
	hsgx	Fair Market Value Of Private Placement Warrants At Issuance FairMarketValueOfPrivatePlacementWarrantsAtIssuance	30704000
	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-25197000
	hsgx	Contractual Agreement Month Year ContractualAgreementMonthYear	2016-05
	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-74000
CY2015Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.61
CY2015Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	362000
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2191000
CY2015Q3	us-gaap	Depreciation Depreciation	414000
CY2015Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2015Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	266000
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39000
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-16000
CY2015Q3	us-gaap	Operating Expenses OperatingExpenses	8039000
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P7Y5M23D
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2015Q3	us-gaap	Interest Expense InterestExpense	23000
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-8039000
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.608	pure
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0179	pure
CY2015Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	5848000
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.601	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.22
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0173	pure
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2015Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2015Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13238997	shares
CY2015Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-8078000
CY2016Q3	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	3056000
CY2016Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.70
CY2016Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	435000
CY2016Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1768000
CY2016Q3	us-gaap	Depreciation Depreciation	404000
CY2016Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-539000
CY2016Q3	us-gaap	Sales Revenue Net SalesRevenueNet	0
CY2016Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	248000
CY2016Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-2667000
CY2016Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-130000
CY2016Q3	us-gaap	Operating Expenses OperatingExpenses	6648000
CY2016Q3	us-gaap	Net Income Loss NetIncomeLoss	-9315000
CY2016Q3	us-gaap	Interest Expense InterestExpense	20000
CY2016Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-6648000
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Term1 ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedTerm1	P6Y11M19D
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0.000	pure
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Volatility Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedVolatilityRate	0.632	pure
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Risk Free Interest Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodRiskFreeInterestRate	0.0153	pure
CY2016Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	4880000
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.852	pure
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.47
CY2016Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0136	pure
CY2016Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y29D
CY2016Q3	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0.000	pure
CY2016Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13297546	shares
CY2016Q3	hsgx	Net Income Loss Available To Common Stockholders Basic And Diluted NetIncomeLossAvailableToCommonStockholdersBasicAndDiluted	-9234000
CY2016Q3	hsgx	Net Income Loss Available To Series A Preferred Stock NetIncomeLossAvailableToSeriesAPreferredStock	-81000

Files In Submission

Name	View Source	Status
0001193125-16-765874-index-headers.html	Edgar Link	pending
0001193125-16-765874-index.html	Edgar Link	pending
0001193125-16-765874.txt	Edgar Link	pending
0001193125-16-765874-xbrl.zip	Edgar Link	pending
d241697d10q.htm	Edgar Link	pending
d241697dex311.htm	Edgar Link	pending
d241697dex312.htm	Edgar Link	pending
d241697dex321.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
hsgx-20160930.xml	Edgar Link	completed
hsgx-20160930.xsd	Edgar Link	pending
hsgx-20160930_cal.xml	Edgar Link	unprocessable
hsgx-20160930_def.xml	Edgar Link	unprocessable
hsgx-20160930_lab.xml	Edgar Link	unprocessable
hsgx-20160930_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OCGN
Ocugen, Inc. Stock $ocgn

2016 Q4 Form 10-Q Financial Statement

#000119312516765874 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN Ocugen, Inc. Stock $ocgn

2016 Q4 Form 10-Q Financial Statement

#000119312516765874 Filed on November 10, 2016

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OCGN
Ocugen, Inc. Stock $ocgn